Abstract
During ontogeny, hematopoietic stem and progenitor cells arise from hemogenic
endothelium through an endothelial-to-hematopoietic transition strictly dependent on the transcription factor RUNX1. Although it is well established that RUNX1 is critical for the onset of hematopoiesis, little is known about the role of RUNX1 dosage specifically in hemogenic endothelium and during the endothelial-to-hematopoietic transition. Here we used the mouse embryonic stem cell differentiation system to determine if and how RUNX1 dosage affects hemogenic endothelium differentiation. The use of inducible Runx1 expression combined with alterations in the expression of RUNX1 cofactor CBFβ allowed us to evaluate a wide range of RUNX1 levels. We demonstrate that low RUNX1 levels are sufficient and necessary to initiate an effective endothelial-to-hematopoietic transition. Subsequently, RUNX1 is also required to complete the endothelial-to
hematopoietic transition and to generate functional hematopoietic precursors. In
contrast, elevated levels of RUNX1 are able to drive an accelerated endothelial-to
hematopoietic transition, but the resulting cells are unable to generate mature hematopoietic cells. Together, our results suggest that RUNX1 dosage plays a pivotal role in hemogenic endothelium maturation and the establishment of the hematopoietic system.
endothelium through an endothelial-to-hematopoietic transition strictly dependent on the transcription factor RUNX1. Although it is well established that RUNX1 is critical for the onset of hematopoiesis, little is known about the role of RUNX1 dosage specifically in hemogenic endothelium and during the endothelial-to-hematopoietic transition. Here we used the mouse embryonic stem cell differentiation system to determine if and how RUNX1 dosage affects hemogenic endothelium differentiation. The use of inducible Runx1 expression combined with alterations in the expression of RUNX1 cofactor CBFβ allowed us to evaluate a wide range of RUNX1 levels. We demonstrate that low RUNX1 levels are sufficient and necessary to initiate an effective endothelial-to-hematopoietic transition. Subsequently, RUNX1 is also required to complete the endothelial-to
hematopoietic transition and to generate functional hematopoietic precursors. In
contrast, elevated levels of RUNX1 are able to drive an accelerated endothelial-to
hematopoietic transition, but the resulting cells are unable to generate mature hematopoietic cells. Together, our results suggest that RUNX1 dosage plays a pivotal role in hemogenic endothelium maturation and the establishment of the hematopoietic system.
Original language | English |
---|---|
Journal | Development |
Early online date | 12 Mar 2018 |
DOIs | |
Publication status | Published - 2018 |
Keywords
- RUNX1
- Hemogenic endothelium
- Dosage
- EHT
- CBFβ
- SOX7
Research Beacons, Institutes and Platforms
- Manchester Cancer Research Centre